Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The Clinic - Seite 2

Pietro Puglisi, Managing Partner at Claris, added: "We are pleased to embark on this strategic partnership with Evotec. The agreement enhances our ability to expedite the progression of our portfolio companies from discovery to clinical stages. Evotec's integrated services have proven instrumental in advancing IAMA Therapeutics' lead programme, IAMA-6, and we look forward to leveraging their expertise to further accelerate the development of transformative drug candidates within our expanding portfolio. This collaboration aligns with Claris's commitment to fostering innovation and delivering impactful solutions to address unmet medical needs."

ABOUT CLARIS VENTURES
Claris Ventures SGR is a venture capital firm based in Italy, founded in 2019. Its first fund under management, Claris Biotech I, with €85 million under management, is focused on early-stage investments in high potential biopharma companies arisen from the Italian R&D ecosystem - both local and international. The firm identifies and supports innovation in the pharmaceutical space, investing in new companies with transformational drugs under development. It aims at the highest impact possible on highly unmet patients need, building value around strong science. Claris Ventures SGR pursuit for high potential projects involves every research center, clinical structure and company in the Italian life sciences network, whether the founding team is based in Italy or it includes Italian scientists abroad who have strong links with Italy. For additional information please go to www.clarisventures.com and follow us on LinkedIn.

ABOUT EVOTEC SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's 17 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 10,04€, was eine Steigerung von +4,51% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

Vontobel

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer